Zanubrutinib Capsules. 商品名称: 百悦泽/BRUKINSA.

Zebutinib capsules are indicated for the treatment of: Adult mantle cell lymphoma (MCL) patients who have received at least one previous treatment. Adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who have received at least one previous treatment. The above indications were conditionally approved based on the objective response rate results of a single-arm clinical trial. The full approval of this product will depend on the results of the ongoing confirmatory randomized controlled clinical trials.
Zebutinib is a selective inhibitor of Bruton’s tyrosine kinase (BTK), which inhibits BTK activity by covalently binding to the cysteine ​​at site 481 of the BTK protein, thereby inhibiting its tyrosine phosphorylation at site 223. It inhibits the growth of Rec-1 mantle cell lymphoma cells and TMD-8 diffuse large B-lymphoma cells in a dose-dependent manner.